EN 
FR 
Board of Directors
Meet the members of Cytel’s Board of Directors, a group of industry leaders and visionaries dedicated to guiding our company towards sustained success and innovation.
Jovan Willford
Chief Executive Officer
Jovan Willford is an accomplished leader known for innovation and transformation, with deep experience in technology-enabled services, clinical processes, and data sciences.
David P. King
Chair of the Board
David P. King is a experienced healthcare executive and former CEO of Labcorp (NYSE: LH), where he led the company’s transformation into a global life sciences leader. Under his leadership, Labcorp tripled in size, entered the Fortune 500, and expanded its presence to more than 100 countries.
David currently serves as Board Chair of Privia Health (PRVA) and serves on the Board of Smith & Nephew (SNN). He is a board member of Novant Health and serves on the advisory board for Duke University’s Robert J. Margolis, MD, Institute for Health Policy.
David holds a bachelor’s degree, cum laude, from Princeton University and a Juris Doctor, cum laude, from the University of Pennsylvania Law School.
Daniel Berglund
Partner | Co-Head of Healthcare | Head of U.S., Nordic Capital Advisors
Daniel is Co-Head of the Healthcare sector and has served on the boards of 13 Nordic Capital portfolio companies across healthcare and software. Daniel focuses on investments situations across the healthcare spectrum with a particular focus on the intersection of healthcare and software. Before joining Nordic Capital in January 2010 he worked at Bain & CO. Daniel holds an MSc in Economics and Business Administration from the Stockholm School of Economics and the Ross School of Business at the University of Michigan.
Judith Charpentier
Partner, Astorg
Judith joined Astorg in 2009. She leads the Healthcare franchise globally at Astorg and serves on the board of several healthcare companies. Before joining Astorg, she worked at Fondations Capital and Morgan Stanley. Judith is an ESSEC graduate and holds a Masters in Political Science from Paris I Panthéon-Sorbonne University.
Maddie Conway Yudkin
Director, Astorg
Maddie joined Astorg in 2022. She worked at Advent International in Boston from 2019 to 2021. Prior to this, she worked in the Healthcare Investment Banking Group at Morgan Stanley. Maddie holds a BA in Economics from Wellesley College.
Joel Davidkin
Partner, Nordic Capital Advisors
Joel joined Nordic Capital in March 2012. He worked in the Investment Banking Division at Goldman Sachs in London from 2010 to February 2012. Joel has an MSc in Finance from Helsinki School of Economics.
Barry Gertz
Independent
Barry joined Blackstone as part of its acquisition of Clarus Funds. He brings 28 years of experience in drug development, from exploratory clinical pharmacology to global Phase 3 trials. This includes development of blockbuster products like Fosamax, Januvia and Keytruda. He is currently a member of the External Advisory Board for the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania School of Medicine. Before joining Clarus, Dr. Gertz was Senior Vice President and Head of Global Clinical Development at Merck. He received an MD, PhD in Pharmacology and a BA from the University of Pennsylvania.
Olivier Lieven
Partner, Astorg
Olivier joined Astorg in 2015. He worked at Barclays and 3i in Paris from 2012 to 2015. Olivier is a graduate civil engineer from Ecole Polytechnique and Ecole Nationale des Ponts et Chaussées in Paris, and holds a Master of Science in Economics from the Paris School of Economics.
Vysh Ravikumaran
Investment Manager, Nordic Capital Advisors
Joined in August 2022. Before joining, Vysh worked as a Senior Associate in the Healthcare team at KKR & Co from 2019 to 2022. Prior, she worked in Singapore at GRAB from 2016 to 2017 and at The Boston Consulting Group from 2014 to 2016. Vysh holds a Masters in Business Administration from Harvard Business School and a Bachelors degree (Hons.) in Economics from the University of Cambridge.
Dr. Rod MacKenzie
Dr. Rod MacKenzie recently retired after 35 years at Pfizer, where he held senior roles, including Chief Development Officer and Executive Vice President. He led the clinical development of key medicines and vaccines, including Comirnaty™ and Paxlovid™. Dr. MacKenzie also represented Pfizer on the board of ViiV Healthcare and chaired the board of TransCelerate.
Dr. MacKenzie began his career as a research scientist in the U.K., co-inventing darifenacin (Enablex™), and holds degrees in organic chemistry from Imperial College London and Columbia University. In 2022, he was appointed Companion of The Order of St Michael and St George by Queen Elizabeth II for his outstanding services to public health.